INVESTORS > Overview

banner-investor

CORPORATE PROFILE

Kips Bay Medical, Inc. was founded in 2007 to develop innovative vascular technology for the cardiac surgeon. We are a medical device company currently focused on manufacturing and commercializing a compelling technology, the eSVS Mesh, which is an external support device for saphenous veins used as bypass conduits in coronary artery bypass grafting (CABG) surgery.

The Kips Bay Medical eSVS Mesh is designed to address the limitations of saphenous vein grafts, or SVGs, used in CABG surgery. The eSVS Mesh is fitted like a sleeve on the outside of the saphenous vein grafts to strengthen SVGs used in CABG surgery. By strengthening the SVG and preventing the damaging expansion of the vein graft, Kips Bay hopes to reduce or prevent the resulting injury which can lead to SVG failure and potentially costly and complicated re-interventions for the patients undergoing CABG surgery. This innovative design is also intended to ensure that blood flow is faster and more laminar by reducing the diameter mis-match between the SVG and target artery.

CABG is one of the most commonly performed cardiac surgeries in the United States. In 2010, there were 395,000 CABG surgeries in the United States alone, and there were estimated to be 165,000 CABG procedures in Europe in 2013. There are, on average, 2+ saphenous vein grafts used per patient.

STOCK QUOTE

KIPS (Common Stock)
PriceChange% ChangeVolume
$0.020.000.00%64,800
Exchange: NASDAQ (US Dollar)
07/31/15 10:59 a.m. ET
Minimum 20 minute delay
Refresh quote

RECENT PRESS RELEASES

DateTitle 
06/29/15Kips Bay Medical Announces an Orderly Wind Down of Operations With the Termination of eMESH I Clinical Feasibility Trial
MINNEAPOLIS, June 29, 2015 (GLOBE NEWSWIRE) -- Kips Bay Medical, Inc. (OTCQB:KIPS) today announced its decision to terminate its eMESH I clinical feasibility trial due to poor early angiographic results from enrolled patients who had an eSVS Mesh implanted using the new surgical implant technique and its intention to effect an orderly wind down of its operations. The eMESH I clinical feasibility trial was a multi-center, randomized study of external saphenous vein graft (SVG) support using t... 
Printer Friendly Version
05/12/15Kips Bay Medical Provides Clinical Trial Update and Reports First Quarter 2015 Results
MINNEAPOLIS, May 12, 2015 (GLOBE NEWSWIRE) -- Kips Bay Medical, Inc. (OTCQB:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS® Mesh, for use in coronary artery bypass grafting surgery, today provided a clinical trial update and announced financial results for its first quarter ended March 28, 2015. Feasibility Study Update During the first quarter of 2015, enrollment in the eMESH I clinical feasibility trial ... 
Printer Friendly Version
03/24/15Kips Bay Medical Announces $3.25 Million Private Placement Bridge Financing
Investors Include Manny Villafaña and Kips Bay Investments, LLC Kips Bay Also Announces New Employment Agreement With Manny Villafaña That Contemplates CEO Succession Plan MINNEAPOLIS, March 24, 2015 (GLOBE NEWSWIRE) -- Kips Bay Medical, Inc. (OTCQB:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS® Mesh, for use in coronary artery bypass grafting surgery, today announced that the Company has entered in... 
Printer Friendly Version
03/12/15Kips Bay Medical Announces Achievement of Enrollment Goal and Provides Business Update and Fourth Quarter and Full Year 2014 Results
MINNEAPOLIS, March 12, 2015 (GLOBE NEWSWIRE) -- Manny Villafaña, Chairman and Chief Executive Officer of Kips Bay Medical, Inc. (OTCQB:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS® Mesh, for use in coronary artery bypass grafting surgery, today announced that the Company had reached its targeted enrollment goal for its eMESH I clinical feasibility trial and provided a business update and financial results for it... 
Printer Friendly Version
More >>

ANNUAL REPORT

Download Documentation 2013 Annual Report (Proxy Statement and Form 10-K)

CORPORATE PROFILE
Kips Bay Medical, Inc. was founded in 2007 to develop innovative vascular technology for the cardiac surgeon. We are a medical device company currently focused on manufacturing and commercializing a compelling technology, the eSVS Mesh, which is an external support device for saphenous veins used as bypass conduits in coronary artery bypass grafting (CABG) surgery.

The Kips Bay Medical eSVS Mesh is designed to address the limitations of saphenous vein grafts, or SVGs, used in CABG surgery. The eSVS Mesh is fitted like a sleeve on the outside of the saphenous vein grafts to strengthen SVGs used in CABG surgery. By strengthening the SVG and preventing the damaging expansion of the vein graft, Kips Bay hopes to reduce or prevent the resulting injury which can lead to SVG failure and potentially costly and complicated re-interventions for the patients undergoing CABG surgery. This innovative design is also intended to ensure that blood flow is faster and more laminar by reducing the diameter mis-match between the SVG and target artery.

CABG is one of the most commonly performed cardiac surgeries in the United States. In 2010, there were 395,000 CABG surgeries in the United States alone, and there were estimated to be 165,000 CABG procedures in Europe in 2013. There are, on average, 2+ saphenous vein grafts used per patient.